Skip to main content
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. — Investor Relations & Filings

Ticker · ZBIO ISIN · US98937L1052 US Manufacturing
Open in API
Filings indexed 147 across all filing types
Latest filing 2025-10-09 Director's Dealing
Country US United States of America
Listing US ZBIO

About Zenas BioPharma, Inc.

https://zenasbio.com/

Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company is advancing a pipeline of immunology-based treatments to address significant unmet patient needs. Its two late-stage franchises are obexelimab and orelabrutinib. Obexelimab is an investigational bifunctional monoclonal antibody designed to suppress B cell activity by co-engaging CD19 and FcγRIIb. Orelabrutinib is an investigational, highly selective, CNS-penetrant oral small molecule BTK inhibitor. Zenas aims to become a global leader in providing innovative treatments for patients with autoimmune conditions.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2025-10-09 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-10-09 English
Director's Dealing 2025
Director's Dealing
2025-10-09 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC, which is used for registering securities for public offering. It includes a base prospectus and an at-the-market offering prospectus for common stock, preferred stock, warrants, and debt securities. The document is a detailed registration statement under the Securities Act of 1933, not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or a certification, so it is not RPA or RNS. Confidence is high due to clear identification of the form and content.
2025-10-08 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or transactions that shareholders should know about between periodic reports. The content includes detailed descriptions of a License Agreement, Subscription Agreement, Securities Purchase Agreement, and Registration Rights Agreements, all related to financing and capital raising activities. There are no comprehensive financial statements or management discussion typical of Annual or Interim Reports. The document focuses on capital raising transactions, private placements, and related agreements, which aligns with Capital/Financing Update filings. The length and detail confirm it is not a brief announcement or a simple notice but a substantive report on financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-10-08 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.